MoonLake Pharmaceuticals, a UK-based biotechnology company, has announced the results of its phase 3 clinical trial for its hidradenitis suppurativa treatment. The trial, which involved over 1,000 patients, showed significant improvement in hidradenitis suppurativa symptoms, with 70% of patients experiencing a reduction in symptoms compared to 40% in the placebo group.
The results of the trial are a significant breakthrough in the treatment of hidradenitis suppurativa, a chronic skin condition that affects thousands of people in the UK. The condition causes painful abscesses and nodules on the skin, and can have a significant impact on a person's quality of life.
MoonLake's treatment has the potential to bring relief to thousands of UK patients suffering from this condition, and the company's shares have risen in response to the positive trial results. The treatment is expected to be submitted for regulatory approval in the coming months, with the potential to be available on the NHS in the UK.
Analysts are optimistic about the potential of MoonLake's treatment, with one analyst describing it as a 'game-changer' in the treatment of hidradenitis suppurativa. The company's shares have risen by 25% in response to the positive trial results, with investors eager to capitalise on the potential of this breakthrough therapy.